Ballast Advisors LLC Has $947,000 Stake in Danaher Co. (NYSE:DHR)

Ballast Advisors LLC grew its stake in Danaher Co. (NYSE:DHR) by 10.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,127 shares of the conglomerate’s stock after purchasing an additional 376 shares during the period. Ballast Advisors LLC’s holdings in Danaher were worth $947,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Heck Capital Advisors LLC bought a new stake in shares of Danaher during the fourth quarter worth $27,000. Decker Retirement Planning Inc. bought a new stake in Danaher during the 4th quarter worth $31,000. Golden State Wealth Management LLC acquired a new position in Danaher in the 4th quarter worth about $31,000. Strategic Financial Concepts LLC bought a new position in Danaher in the fourth quarter valued at about $31,000. Finally, Pineridge Advisors LLC boosted its stake in shares of Danaher by 63.3% during the fourth quarter. Pineridge Advisors LLC now owns 147 shares of the conglomerate’s stock valued at $34,000 after purchasing an additional 57 shares in the last quarter. 79.05% of the stock is owned by institutional investors.

Insider Buying and Selling at Danaher

In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of Danaher stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total value of $1,277,541.00. Following the transaction, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at approximately $4,534,149.90. The trade was a 21.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 10.90% of the company’s stock.

Danaher Stock Performance

NYSE:DHR opened at $210.14 on Friday. The stock has a 50-day moving average price of $217.92 and a 200 day moving average price of $239.26. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. Danaher Co. has a 12-month low of $196.80 and a 12-month high of $281.70. The stock has a market capitalization of $150.19 billion, a P/E ratio of 39.80, a P/E/G ratio of 2.66 and a beta of 0.82.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, hitting the consensus estimate of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same quarter in the previous year, the business posted $2.09 EPS. Equities research analysts forecast that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be issued a dividend of $0.32 per share. The ex-dividend date of this dividend is Friday, March 28th. This represents a $1.28 dividend on an annualized basis and a yield of 0.61%. This is a positive change from Danaher’s previous quarterly dividend of $0.27. Danaher’s dividend payout ratio is currently 24.24%.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on DHR. Scotiabank began coverage on Danaher in a research note on Monday, December 23rd. They issued a “sector perform” rating and a $265.00 price objective for the company. Citigroup dropped their price target on shares of Danaher from $285.00 to $265.00 and set a “buy” rating for the company in a research note on Thursday, January 30th. Stifel Nicolaus upgraded shares of Danaher from a “hold” rating to a “buy” rating and set a $260.00 price target on the stock in a report on Friday, March 14th. Raymond James restated a “market perform” rating on shares of Danaher in a report on Monday, February 3rd. Finally, Robert W. Baird reduced their price target on Danaher from $277.00 to $268.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 28th. Six research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $277.76.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.